NCT05497401View on ClinicalTrials.gov

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

October 31, 2028

Conditions

ARDS

Interventions

BIOLOGICAL

MesenCure

Enhanced mesenchymal cell-based product

OTHER

Placebo

Saline

All Listed Sponsors

lead

BonusBio Group Ltd

INDUSTRY